Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000160) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
DART anti-HIV Env/CD3 MGD014
|
|||||
| Synonyms |
DART MGD014
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Research | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS028 | [1] | ||||
| Scaffold Name | DART | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Binder | Human immunodeficiency virus type 1 infection [ICD-11: XN8LD] | N.A. | MacroGenics | [1] | |
| Envelope glycoprotein gp160 | Binder | Human immunodeficiency virus type 1 infection [ICD-11: XN8LD] | N.A. | MacroGenics | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03570918 | Click to show the Detail | |||||
| Indication | HIV-1-infection | |||||
| Phase | Phase I | |||||
| Title | A Phase I Study to Evaluate the Safety, Immunologic and Virologic Responses of?MGD014?Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | |||||
| Status | Recruiting | |||||
| Sponsor | MacroGenics | |||||
| NCT05261191 | Click to show the Detail | |||||
| Indication | Human Immunodeficiency Virus I Infection; Immunodeficiency Virus Type 1, Human; Human Immunodeficiency Virus Type 1 | |||||
| Phase | Phase I | |||||
| Title | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy | |||||
| Status | Recruiting | |||||
| Sponsor | MacroGenics | |||||